Core Viewpoint - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, enhancing its financial structure and accelerating international commercialization efforts [1] Group 1: Licensing Agreement Details - GSK will obtain exclusive global rights for the development, production, and commercialization of two siRNA products, one of which is in the IND stage and the other is a preclinical candidate [1] - Frontier Biotech will receive an upfront payment of $40 million and a near-term milestone payment of $13 million, with potential cumulative milestone payments of up to $950 million based on development, regulatory, and commercialization achievements [1] - Frontier Biotech will conduct Phase I clinical trials for one product in China and support IND research for the other, while GSK will lead global clinical development and commercialization activities [1] Group 2: Financial Performance and Projections - Frontier Biotech's revenue for 2022-2024 is projected to be approximately $8.474 million, $11.4 million, and $12.9 million, respectively, with net losses of $357 million, $329 million, and $201 million due to high R&D expenditures [2] - For 2025, the company expects revenue of $14 million to $14.5 million, representing a year-on-year growth of 8.13% to 11.99%, primarily driven by sales of its innovative HIV drug and other products [2] - The projected R&D expenses for 2025 are estimated to be between $13.8 million and $14.5 million, reflecting a growth of 0.58% to 5.68% as the company focuses on small RNA drug development [2] Group 3: Profitability Outlook - The company anticipates a net loss attributable to shareholders of between $255 million and $290 million for 2025, an increase in losses of approximately $53.6 million to $88.6 million, mainly due to the absence of investment income from the disposal of a subsidiary's equity in 2024 [3]

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan Biotech, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan Biotech has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The company is advancing its drug pipeline with LDR2402, a long-acting antihypertensive drug targeting AGT, which has entered Phase II clinical trials and completed the first dosing of a subject [1] - An IND application for LDR2515, a small nucleic acid drug for obesity treatment targeting INHBE, has received implied approval from the CDE [1] Group 2: Financial and Investment Details - Chengdu XianDao plans to invest up to 15 million yuan in XianYuan Biotech, which has a registered capital of 17.24 million yuan [1] - Prior to this transaction, Chengdu XianDao held a 23.20% stake in XianYuan Biotech and intends to subscribe to an additional capital increase of 24 million yuan based on a pre-investment valuation of 450 million yuan [1] - The lead investor in this financing round is Chengdu TianShi DaoYuan GuoSheng Medical Health Venture Capital Partnership, with other investors including related parties [1]

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The ultra-long-acting antihypertensive drug LDR2402 targeting the AGT site has entered Phase II clinical trials, with the first subject already dosed [1] - The clinical trial application (IND) for the small nucleic acid new drug LDR2515 injection (targeting INHBE) for obesity treatment has recently received implied approval from the China National Medical Products Administration (CDE) [1] Group 2: Financing and Shareholding - XianYuan is a subsidiary and affiliated party of Chengdu XianDao, with a registered capital of 17.24 million yuan [1] - Chengdu XianDao plans to subscribe to an additional registered capital of 24 million yuan at a pre-investment valuation of 450 million yuan, increasing its shareholding in XianYuan from 23.20% [1] - The lead investor in this financing round is Chengdu Angel DaoYuan GuoSheng Medical Health Venture Capital Partnership (Limited Partnership), with other investors including affiliated parties Cao Jiaming and Huabo Medical [1]

Core Viewpoint - Frontier Biotech has disclosed its performance forecast for the fiscal year 2025, expecting revenue growth while still facing net profit losses due to ongoing investments in R&D and operational costs [1] Group 1: Financial Performance - The company anticipates revenue between 140 million to 145 million yuan for 2025, representing a year-on-year increase of 8.13% to 11.99% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be a loss of approximately 288 million to 323 million yuan, which indicates a reduction in losses by about 4.31 million to 39.31 million yuan compared to the previous year [1] Group 2: Revenue Sources - Revenue is primarily derived from the sales of the anti-HIV innovative drug Aikening® and the recently approved far-infrared therapy patch [1] - The reduction in net profit losses is attributed to increased revenue and decreased operating expenses [1] Group 3: R&D Investments - The company plans to invest approximately 138 million to 145 million yuan in R&D for 2025, reflecting a year-on-year increase of 0.58% to 5.68% [1] - The focus of R&D is on small nucleic acid new drug development and early-stage research of other new drugs [1] Group 4: R&D Pipeline - Frontier Biotech is developing a multi-tiered R&D pipeline, with a focus on antiviral business and small nucleic acid innovative drugs as the core development line, supplemented by high-end generic drugs [1] - The company has submitted an IND application for the single-target small nucleic acid drug FB701, which has been accepted for clinical application approval [2] - The dual-target small nucleic acid drug FB7011 has entered supportive research for new drug clinical trial applications, and the preclinical candidate molecule for FB7023 has been identified [2] - The company has also initiated preclinical research for FB2004, a novel interferon-α2 mutant, in collaboration with Fudan University [2] - The generic drug FB3002 for treating musculoskeletal pain has received acceptance for its market approval application and is currently under review [2]

Core Viewpoint - Frontier Biopharmaceuticals (Nanjing) Co., Ltd. forecasts a revenue increase for 2025, while also projecting a higher net loss compared to the previous year, primarily due to the absence of investment gains from subsidiary disposals in 2024 [2][5]. Group 1: Performance Forecast - The company expects to achieve an operating revenue of approximately CNY 140 million to CNY 145 million in 2025, representing a year-on-year increase of 8.13% to 11.99% [2][5]. - The projected net loss attributable to shareholders is estimated to be between CNY 255 million and CNY 290 million, an increase in loss of approximately CNY 53.62 million to CNY 88.62 million compared to 2024 [2][5]. - The net loss excluding non-recurring gains and losses is expected to be between CNY 288 million and CNY 323 million, a reduction in loss of approximately CNY 4.31 million to CNY 39.31 million, mainly due to revenue growth and reduced expenses [2][5]. Group 2: Revenue Sources - Revenue is primarily derived from the sales of the innovative anti-HIV drug Aikening (generic name: Aibowei Tai), the agency product Viread (Tenofovir), and the newly approved far-infrared therapeutic patch (Xiaoyan Yipai) [2][5]. - The sales of Aikening are focused on the inpatient market, with continued growth in outpatient revenue, supported by its reputation as a preferred medication for hospitalized patients [5][6]. Group 3: R&D and Commercialization Progress - The company is focusing on the research and development of small nucleic acid drugs and has submitted IND applications for several candidates, including FB7013 and FB7011, which are in various stages of clinical development [7][8]. - The company has completed nationwide sales registration for the agency product Viread and has initiated commercial promotion for the far-infrared therapeutic patch [6][8]. - R&D expenses are projected to be between CNY 138 million and CNY 145 million, reflecting a year-on-year increase of 0.58% to 5.68%, as the company emphasizes early-stage development of new drugs [5][7].